Table 3.
Hazard ratios (HR) and log-rank P values of the assessed biomarkers associated with poor prognosis in patients with mutated AMLs
| Type of AML mutation (n) | Hazard ratio (HR) | Log-rank P |
|---|---|---|
|
IDH1 mutation (n = 51) |
NDUFA6: 3.28 (1.41–7.64) | 0.0037 |
| SDHA: 2.1 (1.02- 4.32) | 0.0405 | |
| CPT1A: 2.68 (1.32–5.43) | 0.0044 | |
|
IDH2 mutation (n = 57) |
NDUFA6: 2.45 (1.14–5.25) | 0.0178 |
| CPT1A: 2.48 (1.25–4.92) | 0.007 | |
|
NPM1 mutation (n = 217) |
NDUFA6:1.85 (1.18–2.88) | 0.0059 |
| SDHA: 1.67 (1.16.2.41) | 0.0057 | |
| CYB5A: 1.49 (1.05–2.1) | 0.0245 | |
| SLC25A12: 1.79 (1.18–2.73) | 0.0055 | |
| ETFB: 1.54 (1.07–2.21) | 0.0191 | |
| CPT1A: 1.45 (1.02–2.06) | 0.035 | |
|
FLT3-ITD mutation (n = 191) |
NDUFA6: 1.5 (1.07–2.1) | 0.0188 |
| SDHA: 2.59 (1.85–3.64) | 1e-08 | |
| CYB5A: 1.5 (1.06–2.13) | 0.0198 | |
|
SLC25A12: 1.58 (1.13–2.2) ETFB: 1.58 (1.12–2.23) |
0.0065 0.0079 |
|
| CPT1A: 2.09 (1.5–2 | 9.9e-06 | |
|
FLT3-TKD mutation (n = 79) |
SDHA: 2.17 (1.14–4.14) | 0.0163 |
| ETFB: 2.48 (1.31–4.7) | 0.0041 | |
| CPT1A: 3.41 (1.42–8.17) | 0.003 | |
|
CEBPA mutation (n = 52) |
SLC25A12: 4.48 (1.32–15.18) | 0.0084 |
| CPT1A: 2.57 (1.11–5.95) | 0.023 |
IDH1 isocitrate dehydrogenase 1, IDH2 isocitrate dehydrogenase 2, NPM1 nucleophosmin 1, ITD internal tandem duplication, TKD tyrosine kinase domain, CEBPA CCAAT/enhancer-binding protein alpha